Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer


Mangir N., Turkeri L.

ACTAS UROLOGICAS ESPANOLAS, cilt.38, sa.8, ss.515-522, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 38 Konu: 8
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/j.acuro.2013.12.012
  • Dergi Adı: ACTAS UROLOGICAS ESPANOLAS
  • Sayfa Sayıları: ss.515-522

Özet

Introduction: Docetaxel administered every 3-weeks is the standart treatment of castration resistant prostate cancer (CRPC) but it is associated with dose limiting toxicities. We analyzed the efficacy and tolerability of 3- weekly and weekly docetaxel in a Turkish cohort of CRPC patients with a special emphasis on the elderly patients.